Follow us on:

Linkedin Facebook

Agronomics announces sale of InSilico Medicine Inc shares

Laboratory Spiritus Mundi
[shareaholic app="share_buttons" id_name="post_below_content"]

Agronomics plc (LON:ANIC), the leading listed alternative proteins company with a focus on cellular agriculture and cultivated meat, has announced the disposal of its total holding of 23,147 shares in Insilico Medicine Inc for US $669,775 (£475,540), representing an IRR of 54%. Insilico Medicine was a legacy portfolio holding, acquired for £92,755 between June 2017 and July 2018. The proceeds will provide Agronomics with further funding for new and existing opportunities within the field of cellular agriculture.

The remaining legacy positions in the Agronomics portfolio continue to be monitored and will be sold down as opportunities arise.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

    Latest Company News

    Surface Transforms

    Surface Transforms analyst Zeus upgrades forecasts

    Growth

    Fintel core revenue growth is higher than Zeus forecast

    Shoe Zone plc

    Shoe Zone analyst Zeus upgrades FY22 adjusted PBT forecast

    Growth

    LBG Media “significant untapped growth opportunities” says Zeus

    profit

    DWF Group “significant long-term upside” says Zeus

    CentralNic Group long term high accelerating growth yet still room for significant upside (Analyst VIDEO)

      Latest interviews

      View all interviews 

      Company Presentations

      View all Company Presentations

      Brokers Talk

      View all Broker Talk

      FTSE 100 News

      Search

      Search

      Green News

      View all Sustainable sectors, Plcs and news  

      Q&A's

      View all Question and Answers

      Funds

      View all Funds, Market Insights and news

      UK Broker Ratings

      Hardman & Co

      Don't Miss Our News Alerts

      Subscribe Free

      Find us on:

      Linkedin Facebook

      Useful links

      Disclaimer

      You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

      © 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.